Premium
Clinical Risk Factors for Adverse Events in Allopurinol Users
Author(s) -
Ryu Hee Jung,
Song Ran,
Kim Hye Won,
Kim Jin Hyun,
Lee Eun Young,
Lee Yun Jong,
Song Yeong Wook,
Lee Eun Bong
Publication year - 2013
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270012439715
Subject(s) - allopurinol , medicine , adverse effect , gout , odds ratio , hyperuricemia , tumor lysis syndrome , uric acid , risk factor , colchicine , gastroenterology , chemotherapy
Allopurinol, one of the most commonly used uric acid–lowering agents, can cause serious adverse events. To investigate the risk factors for allopurinol‐induced adverse events, the authors enrolled 94 patients who developed allopurinol‐induced adverse events and 378 controls who were randomly chosen from 1934 patients who used allopurinol but did not develop any adverse events in this retrospective case control study. Univariate analysis showed that patients who developed allopurinol‐induced adverse events had more chronic kidney disease (46% vs 30%, P = .005), more hypertension (42% vs 30%, P = .036), less tumor lysis syndrome ( P = .030), higher cholesterol ( P = .013), and lower aspartate aminotransferase ( P = .002) and alanine aminotransferase levels ( P = .033) and more commonly used angiotensin receptor blockers (27% vs 15%, P = .007), colchicines (16% vs 5%, P = .010), or statins (19% vs 8%, P = .002) than those who did not. In multiple logistic regression analysis, the use of colchicines (odds ratio, 3.11; 95% confidence interval, 1.28‐7.58; P = .012) and statins (2.10; 1.03‐4.25; P = .041) was an independent risk factor predicting adverse events in allopurinol users. In conclusion, patients who use colchicine or statins are at significant risk for developing allopurinol‐induced adverse events.